Case report: gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib.

Rearrangements involving the neurotrophin kinase () genes , and with different fusion partners have been observed in both adult and pediatric solid tumors. Larotrectinib and entrectinib have been the first tumor-agnostic compounds approved for the treatment of NTRK fusion-positive tumors. Here, we report the first case of a female patient with a diagnosis of stage IV lung adenocarcinoma harboring the gene fusion, and successfully treated with entrectinib.